Amneal Pharmaceuticals, Inc. AMRX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s long-term debt?
- Amneal Pharmaceuticals, Inc. (AMRX) reported long-term debt of $2.57B in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s long-term debt increased by 19.1% year-over-year, from $2.15B to $2.57B.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s long-term debt has grown at a -1.3% compound annual growth rate (CAGR), from $2.74B to $2.57B.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.